After moving 1.2% during today's afternoon session, Biogen is now trading at a price of $240.31 per share. On average, analysts give it a target price of $330.76.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.
Potential Biogen Investors Should Analyze the Following:
-
Biogen has moved -14.0% over the last year.
-
The company has a price to earnings growth (PEG) ratio of 33.68. A number between 0 and 1 could mean that the market is undervaluing Biogen's estimated growth potential
-
Its Price to Book (P/B) ratio is 2.41
Understanding Biogen's Operating Margins
| Date Reported | Total Revenue ($ k) | Operating Expenses ($ k) | Operating Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2023 | 9,971,500 | 6,850,200 | 31 | -11.43 |
| 2022 | 10,173,400 | 6,581,600 | 35 | 34.62 |
| 2021 | 10,981,700 | 9,236,500 | 26 | -31.58 |
| 2020 | 13,444,600 | 8,397,100 | 38 | -24.0 |
| 2019 | 14,377,900 | 7,335,300 | 50 | 13.64 |
| 2018 | 13,452,900 | 7,564,300 | 44 |
Over the last 6 years, Biogen's operating margins have averaged 37.3%, which is better than the 15.02% Biotechnology industry average. We also note that the company's operating margins have a high coefficient of variability at 73.6%. However the firm's margins are declining at a compounded yearly rate of -5.5%.
